logoCabeceraNinos

Hemos leído sobre ... AIJ Sistématica

Última actualización: 15 Noviembre 2018
 
 
 
OCTUBRE 2018
  • Shenoi S, Horneff G, Cidon M, Ramanan AV, Kimura Y, Quartier P, Foeldvari I, Zeft A, Lomax KG, Gregson J, Abma T, Campbell-Hill S, Weiss J, Patel D, Marinsek N, Wulffraat N.
    The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an internationalsurvey and retrospective chart review.
    Clin Exp Rheumatol. 2018 Sep-Oct;36(5):920-928. Epub 2018 Mar 21
    https://www.ncbi.nlm.nih.gov/pubmed/29600940
  • Feng M, Kang M, He F, Xiao Z, Liu Z, Yao H, Wu J.
    Plasma interleukin-37 is increased and inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells in systemic juvenile idiopathic arthritis patients
    J Transl Med. 2018 Oct 11;16(1):277. doi: 10.1186/s12967-018-1655-8.
    https://www.ncbi.nlm.nih.gov/pubmed/30305171
 
SEPTIEMBRE 2018
  • Ruperto N, Brunner HI, Quartier P, Constantin T, Wulffraat NM, Horneff G, Kasapcopur O, Schneider R, Anton J, Barash J, Berner R, Corona F, Cuttica R, Fouillet-Desjonqueres M, Fischbach M, Foster HE, Foell D, Radominski SC, Ramanan AV, Trauzeddel R, Unsal E, Levy J, Vritzali E, Martini A, Lovell DJ.
    Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials.
    Ann Rheum Dis. 2018 Sep 29. pii: annrheumdis-2018-213150. doi: 10.1136/annrheumdis-2018-213150. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30269054
  • Baris HE, Anderson E, Sozeri B, Dedeoglu F.
    Impact of biologics on disease course in systemic onset juvenile idiopathic arthritis.
    Clin Rheumatol. 2018 Sep 20. doi: 10.1007/s10067-018-4297-6. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30238379
 
AGOSTO 2018
  • Kearsley-Fleet L, Beresford MW, Davies R, De Cock D, Baildam E, Foster HE, Southwood TR, Thomson W, Hyrich KL; Biologics for Children with Rheumatic Diseases Study.
    Short-term outcomes in patients with systemic juvenile idiopathic arthritis treated with either tocilizumab or anakinra.
    Rheumatology (Oxford). 2018 Aug 21. doi: 10.1093/rheumatology/key262. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/30137641
  • Lee JJY, Schneider R.
    Systemic Juvenile Idiopathic Arthritis.
    Pediatr Clin North Am. 2018 Aug;65(4):691-709. doi: 10.1016/j.pcl.2018.04.005.
    https://www.ncbi.nlm.nih.gov/pubmed/30031494
 
JUNIO 2018
  •  Li H, Abramova I, Chesoni S, Yao Q.
    Molecular genetic analysis for periodic fever syndromes: a supplemental role for the diagnosis of adult-onset Still's disease.
    Clin Rheumatol. 2018 Jun 17. doi: 10.1007/s10067-018-4178-z
    https://www.ncbi.nlm.nih.gov/pubmed/29909561
  • Ter Haar NM, Tak T, Mokry M, Scholman RC, Meerding JM, de Jager W, Verwoerd A, Foell D, Vogl T, Roth J, Leliefeld PHC, van Loosdregt J, Koenderman L, Vastert SJ, de Roock S.
    Reversal of Sepsis-Like Features of Neutrophils by Interleukin-1 Blockade in Patients With Systemic-Onset Juvenile Idiopathic Arthritis.
    Arthritis Rheumatol. 2018 Jun;70(6):943-956. doi: 10.1002/art.40442
    https://www.ncbi.nlm.nih.gov/pubmed/29426067
  • Schulert GS, Zhang M, Husami A, Fall N, Brunner H, Zhang K, Cron RQ, Grom AA.
    Brief Report: Novel UNC13D Intronic Variant Disrupting an NF-κB Enhancer in a Patient With Recurrent Macrophage Activation Syndrome and Systemic Juvenile Idiopathic Arthritis.
    Arthritis Rheumatol. 2018 Jun;70(6):963-970. doi: 10.1002/art.40438.
    https://www.ncbi.nlm.nih.gov/pubmed/29409136
  • Toplak N, Blazina Š, Avčin T.
    The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives.
    Drug Des Devel Ther. 2018 Jun 8;12:1633-1643. doi: 10.2147/DDDT.S114532
    https://www.ncbi.nlm.nih.gov/pubmed/29922038
 
MAYO 2018
  • Hügle B, Schippers A, Fischer N, Ohl K, Denecke B, Ticconi F, Vastert B, Costa IG, Haas JP, Tenbrock K.
    Transcription factor motif enrichment in whole transcriptome analysis identifies STAT4 and BCL6 as the most prominent binding motif in systemic juvenile idiopathic arthritis.
    Arthritis Res Ther. 2018 May 30;20(1):98. doi: 10.1186/s13075-018-1603-2.
    https://www.ncbi.nlm.nih.gov/pubmed/29848367
  • Sakumura N, Shimizu M, Mizuta M, Inoue N, Nakagishi Y, Yachie A.
    Soluble CD163, a unique biomarker to evaluate the disease activity, exhibits macrophage activation in systemic juvenile idiopathic arthritis.
    Cytokine. 2018 May 23. pii: S1043-4666(18)30216-3. doi: 10.1016/j.cyto.2018.05.017. [Epub ahead of print]
    https://www.ncbi.nlm.nih.gov/pubmed/29801971
 
ABRIL 2018
    • Bielak M, Husmann E, Weyandt N, Haas JP, Hügle B, Horneff G, Neudorf U, Lutz T, Lilienthal E, Kallinich T, Tenbrock K, Berendes R, Niehues T, Wittkowski H, Weißbarth-Riedel E, Heubner G, Oommen P, Klotsche J, Foell D, Lainka E.
      IL-6 blockade in systemic juvenile idiopathic arthritis - achievement of inactive disease and remission (data from the German AID-registry).
      Pediatr Rheumatol Online J. 2018 Apr 5;16(1):22. doi: 10.1186/s12969-018-0236-y.
      https://www.ncbi.nlm.nih.gov/pubmed/29622022
    • Yasuoka R, Iwata N, Abe N, Kohagura T, Nakaseko H, Shimizu M, Kawabe S.
      Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis.
      Mod Rheumatol. 2018 Apr 16:1-4. doi: 10.1080/14397595.2018.1457490. [Epub ahead of print]
      https://www.ncbi.nlm.nih.gov/pubmed/29578355
 
MARZO 2018
      • Vastert SJ, Nigrovic PA.
        Toward personalized treatment for systemic juvenile idiopathic arthritis.
        Arthritis Rheumatol. 2018 Mar 23. doi: 10.1002/art.40501. [Epub ahead of print] 
        https://www.ncbi.nlm.nih.gov/pubmed/29569852
      • Yasuoka R, Iwata N, Abe N, Kohagura T, Nakaseko H, Shimizu M, Kawabe S.
        Risk factors for hypersensitivity reactions to tocilizumab introduction in systemic juvenile idiopathic arthritis.
        Mod Rheumatol. 2018 Mar 26:1-12.
        https://www.ncbi.nlm.nih.gov/pubmed/29578355
      • Feist E, Quartier P, Fautrel B, Schneider R, Sfriso P, Efthimiou P, Cantarini L, Lheritier K, Leon K, Karyekar CS, Speziale A
        Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.
        Clin Exp Rheumatol. 2018 Mar 2. [Epub ahead of print] 
        https://www.ncbi.nlm.nih.gov/pubmed/29533755
      • Nigrovic PA, Beukelman T, Tomlinson G, Feldman BM, Schanberg LE, Kimura Y; Childhood Arthritisand Rheumatology Research Alliance Systemic Juvenile Idiopathic Arthritis
        Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST).Consensus Treatment Plan Workgroup.
        Clin Trials. 2018 Mar 1:1740774518761367. doi: 10.1177/1740774518761367. [Epub ahead of print] 
        https://www.ncbi.nlm.nih.gov/pubmed/29542334
      • Shenoi S, Horneff G, Cidon M, Ramanan AV, Kimura Y, Quartier P, Foeldvari I, Zeft A, Lomax KG, Gregson J, Abma T, Campbell-Hill S, Weiss J, Patel D, Marinsek N, Wulffraat N.
        The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review.
        Clin Exp Rheumatol. 2018 Mar 21. [Epub ahead of print] 
        https://www.ncbi.nlm.nih.gov/pubmed/29600940
      • Stringer T, Gittler J, Meehan S, Kahn P, Oza VS.
        Neutrophilic urticarial dermatosis as a presenting feature of systemic juvenile idiopathic arthritis.
        Pediatr Dermatol. 2018 Mar 25. doi: 10.1111/pde.13464. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/29574969
 
FEBRERO 2018
      • Leurs A, Launay D, Terriou L, Hatron PY, Quartier P, Hachulla E.
        Remission of Refractory Systemic-Onset Juvenile Idiopathic Arthritis After Treatment With Siltuximab.
        J Clin Rheumatol. 2018 Feb 27. doi: 10.1097/RHU.0000000000000716. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/29485546
      • Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ.
        Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.
        Ann Rheum Dis. 2018 Feb 22. pii: annrheumdis-2017-212608. doi: 10.1136/annrheumdis-2017-212608. [Epub ahead of print]
        https://www.ncbi.nlm.nih.gov/pubmed/29472362
 
ENERO 2018
    • Hinze CH, Holzinger D, Lainka E, Haas JP, Speth F, Kallinich T, Rieber N, Hufnagel M, Jansson AF, Hedrich C, Winowski H, Berger T, Foeldvari I, Ganser G, Hospach A, Huppertz HI, Mönkemöller K, Neudorf U, Weißbarth-Riedel E, Wittkowski H, Horneff G, Foell D; PRO-KIND SJIA project collaborators.
      Practice and consensus-based strategies in diagnosing and managing systemic juvenile idiopathic arthritis in Germany.
      Pediatr Rheumatol Online J. 2018 Jan 22;16(1):7. doi: 10.1186/s12969-018-0224-2.
      https://www.ncbi.nlm.nih.gov/pubmed/29357887
PATROCINADORES

Área de Socios